KILITCH DRUGS (INDIA) LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹208.4
- Today's High:
- ₹227.5
- Open Price:
- ₹227.5
- 52W Low:
- ₹121.3
- 52W High:
- ₹237
- Prev. Close:
- ₹219.3
- Volume:
- 6267
Company Statistics
- Market Cap.:
- ₹2.84 billion
- Book Value:
- 97.415
- Revenue TTM:
- ₹1.40 billion
- Operating Margin TTM:
- 10.04%
- Gross Profit TTM:
- ₹677.58 million
- Profit Margin:
- 7.48%
- Return on Assets TTM:
- 4.08%
- Return on Equity TTM:
- 5.7%
Company Profile
KILITCH DRUGS (INDIA) LTD. had its IPO on under the ticker symbol KILITCH.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. KILITCH DRUGS (INDIA) LTD. has a staff strength of 0 employees.
Stock update
Shares of KILITCH DRUGS (INDIA) LTD. opened at ₹227.5 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹208.4 - ₹227.5, and closed at ₹217.1.
This is a -1% slip from the previous day's closing price.
A total volume of 6,267 shares were traded at the close of the day’s session.
In the last one week, shares of KILITCH DRUGS (INDIA) LTD. have increased by +12.23%.
KILITCH DRUGS (INDIA) LTD.'s Key Ratios
KILITCH DRUGS (INDIA) LTD. has a market cap of ₹2.84 billion, indicating a price to book ratio of 1.7338 and a price to sales ratio of 1.8551.
In the last 12-months KILITCH DRUGS (INDIA) LTD.’s revenue was ₹1.40 billion with a gross profit of ₹677.58 million and an EBITDA of ₹175.66 million. The EBITDA ratio measures KILITCH DRUGS (INDIA) LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, KILITCH DRUGS (INDIA) LTD.’s operating margin was 10.04% while its return on assets stood at 4.08% with a return of equity of 5.7%.
In Q1, KILITCH DRUGS (INDIA) LTD.’s quarterly earnings growth was a positive 23.3% while revenue growth was a positive 24.2%.
KILITCH DRUGS (INDIA) LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 26.1119
- PEG
Its diluted EPS in the last 12-months stands at ₹6.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into KILITCH DRUGS (INDIA) LTD.’s profitability.
KILITCH DRUGS (INDIA) LTD. stock is trading at a EV to sales ratio of 1.5942 and a EV to EBITDA ratio of 13.403. Its price to sales ratio in the trailing 12-months stood at 1.8551.
KILITCH DRUGS (INDIA) LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹2.20 billion
- Total Liabilities
- ₹688.73 million
- Operating Cash Flow
- ₹114.66 million
- Capital Expenditure
- ₹2.61 million
- Dividend Payout Ratio
- 0%
KILITCH DRUGS (INDIA) LTD. ended 2024 with ₹2.20 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹2.20 billion while shareholder equity stood at ₹1.52 billion.
KILITCH DRUGS (INDIA) LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹688.73 million in other current liabilities, 155823000.00 in common stock, ₹1.36 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹198.46 million and cash and short-term investments were ₹591.98 million. The company’s total short-term debt was ₹221,935,000 while long-term debt stood at ₹0.
KILITCH DRUGS (INDIA) LTD.’s total current assets stands at ₹1.26 billion while long-term investments were ₹0 and short-term investments were ₹392.18 million. Its net receivables were ₹542.87 million compared to accounts payable of ₹408.75 million and inventory worth ₹20.45 million.
In 2024, KILITCH DRUGS (INDIA) LTD.'s operating cash flow was ₹114.66 million while its capital expenditure stood at ₹2.61 million.
Comparatively, KILITCH DRUGS (INDIA) LTD. paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹217.1
- 52-Week High
- ₹237
- 52-Week Low
- ₹121.3
- Analyst Target Price
- ₹
KILITCH DRUGS (INDIA) LTD. stock is currently trading at ₹217.1 per share. It touched a 52-week high of ₹237 and a 52-week low of ₹237. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹190.74 and 200-day moving average was ₹173.65 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7282.7% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About KILITCH DRUGS (INDIA) LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrup, gripe water, and oral powder and liquid in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.